The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Absolute Risk of Endometrial Carcinoma During 20-Year Follow-Up Among Women With Endometrial Hyperplasia
Open accessAbstract
Purpose: The severity of endometrial hyperplasia (EH)—simple (SH), complex (CH), or atypical (AH)—influences clinical management, but valid estimates of absolute risk of clinical progression to carcinoma are lacking. Materials and Methods: We conducted a case-control study nested in a cohort of 7,947 women diagnosed with EH (1970-2002) at one prepaid health plan who remained at risk for at least 1 year. Patient cases (N = 138) were diagnosed with carcinoma, on average, 6 years later (range, 1 to 24 years). Patient controls (N = 241) were matched to patient cases on age at EH, date of EH, and duration of follow-up, and they were counter-matched to patient cases on EH severity. After we independently reviewed original slides and medical records of patient controls and patient cases, we combined progression relative risks (AH v SH, CH, or disordered proliferative endometrium [ie, equivocal EH]) from the case-control analysis with clinical censoring information (ie, hysterectomy, death, or left the health plan) on all cohort members to estimate interval-specific (ie, 1 to 4, 5 to 9, and 10 to 19 years) and cumulative (ie, through 4, 9, and 19 years) progression risks. Results: For nonatypical EH, cumulative progression risk increased from 1.2% (95% CI, 0.6% to 1.9%) through 4 years to 1.9% (95% CI, 1.2% to 2.6%) through 9 years to 4.6% (95% CI, 3.3% to 5.8%) through 19 years after EH diagnosis. For AH, cumulative risk increased from 8.2% (95% CI, 1.3% to 14.6%) through 4 years to 12.4% (95% CI, 3.0% to 20.8%) through 9 years to 27.5% (95% CI, 8.6% to 42.5%) through 19 years after AH. Conclusion: Cumulative 20-year progression risk among women who remain at risk for at least 1 year is less than 5% for nonatypical EH but is 28% for AH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pepe, M. S. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh101 · Cited by 1,276
Kurman, R. J., Kaminski, P. F., & Norris, H. J. (1985) · Cancer · doi:10.1002/1097-0142(19850715)56:2<403::aid-cncr2820560233>3.0.co;2-x · Cited by 1,252
Trimble, C. L., Kauderer, J., Zaino, R., Silverberg, S., Lim, P. C., Burke, J. J., Alberts, D., & Curtin, J. (2006) · Cancer · doi:10.1002/cncr.21650 · Cited by 601
The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia
Ferenczy, A., & Gelfand, M. (1989) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(89)90103-8 · Cited by 224
Building a Research Consortium of Large Health Systems: The Cancer Research Network
Wagner, E. H. (2005) · Journal of the National Cancer Institute Monographs · doi:10.1093/jncimonographs/lgi032 · Cited by 179
Horn, L., Schnurrbusch, U. E. K., Bilek, K., Hentschel, B., & Einenkel, J. (2004) · International Journal of Gynecological Cancer · doi:10.1111/j.1048-891x.2004.014220.x · Cited by 167
Lacey, J. V., Ioffe, O. B., Ronnett, B. M., Rush, B. B., Richesson, D. A., Chatterjee, N., Langholz, B. M., Glass, A. G., & Sherman, M. E. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604102 · Cited by 107
Self-citationEstimation of Absolute Risk from Nested Case-Control Data
Langholz, B. M., & Borgan, Ø. (1997) · Biometrics · doi:10.2307/2533977 · Cited by 101
Self-citationSampling strategies in nested case-control studies.
Langholz, B. M., & Clayton, D. G. (1994) · Environmental Health Perspectives · doi:10.1289/ehp.94102s847 · Cited by 79
Self-citationIII. Endometrial Hyperplasia: Is It Time for a Quantum Leap to a New Classification?*
Zaino, R. J. (2000) · International Journal of Gynecological Pathology · doi:10.1097/00004347-200010000-00004 · Cited by 51
Cited by
Makker, V., MacKay, H., Ray-Coquard, I., Levine, D. A., Westin, S. N., Aoki, D., & Oaknin, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00324-8 · Cited by 674
The Oncogenic Potential of Endometrial Polyps: A Systematic Review and Meta-Analysis
Lee, S. C., Kaunitz, A. M., Sanchez-Ramos, L., & Rhatigan, R. M. (2010) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181f74864 · Cited by 232
Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons.
Bakkum-Gamez, J. N., Wentzensen, N., Maurer, M. J., Hawthorne, K. M., Voss, J. S., Kroneman, T. N., Famuyide, A. O., Clayton, A. C., Halling, K. C., Kerr, S. E., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.01.552 · Cited by 107
Self-citationThe Role of Rapamycin in Healthspan Extension via the Delay of Organ Aging
Zhang, Y., Zhang, J., & Wang, S. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101376 · Cited by 92
Metadata
- Authors
- Lacey, J. V., Sherman, M. E., Rush, B. B., Ronnett, B. M., Ioffe, O. B., Duggan, M. A., Glass, A. G., Richesson, D. A., Chatterjee, N., & Langholz, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-02-10
- Volume
- 28
- Issue
- 5
- Pages
- 788-792
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2095881173
- Cited by
- 277
- References
- 10
- FWCI
- 16.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Absolute Risk of Endometrial Carcinoma During 20-Year Follow-Up Among Women With Endometrial Hyperplasia. https://app.cochat.ai/papers/10.1200/jco.2009.24.1315
- The paper
- Lacey, J. V., Sherman, M. E., Rush, B. B., Ronnett, B. M., Ioffe, O. B., Duggan, M. A., Glass, A. G., Richesson, D. A., Chatterjee, N., & Langholz, B. (2010). Absolute Risk of Endometrial Carcinoma During 20-Year Follow-Up Among Women With Endometrial Hyperplasia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.24.1315
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.